Osimertinib Bests Platinum-Pemetrexed in T790M+ NSCLC

This article originally appeared here.
Share this content:
Osimertinib Bests Platinum-Pemetrexed in T790M+ NSCLC
Osimertinib Bests Platinum-Pemetrexed in T790M+ NSCLC

THURSDAY, Dec. 8, 2016 (HealthDay News) -- Osimertinib is more effective than platinum-pemetrexed therapy in patients with T790M-positive advanced non-small-cell lung cancer whose disease has progressed during first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment, according to a study published online Dec. 6 in the New England Journal of Medicine. The research was published to coincide with the International Association for the Study of Lung Cancer's 17th World Conference on Lung Cancer, held from Dec. 4 to 7 in Vienna.

Tony S. Mok, M.D., from the Chinese University of Hong Kong, and colleagues conducted a phase 3 trial involving 419 patients with T790M-positive advanced non-small-cell lung cancer who had disease progression after first-line EGFR-TKI therapy. Participants were randomized in a 2:1 ratio to oral osimertinib or intravenous pemetrexed plus carboplatin or cisplatin every three weeks for up to six cycles.

The researchers found that progression-free survival was of a significantly longer duration with osimertinib versus platinum therapy plus pemetrexed (10.1 versus 4.4 months; hazard ratio, 0.30). A significantly better objective response rate was seen for osimertinib than platinum therapy plus pemetrexed (71 versus 31 percent; odds ratio, 5.39). The median duration of progression-free survival was significantly longer with osimertinib among the 144 patients with metastases to the central nervous system (CNS) (8.5 versus 4.2 months; hazard ratio, 0.32).

"Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced non-small-cell lung cancer (including those with CNS metastases), in whom disease had progressed during first-line EGFR-TKI therapy," the authors write.

The study was funded by AstraZeneca, the manufacturer of osimertinib.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Trials Highlight Benefits, Risks of Testosterone Treatment

Trials Highlight Benefits, Risks of Testosterone Treatment

While trials show it boosts bone density and lowers anemia risk, heart risks also seen

Exercise Most Important Lifestyle Change for Breast CA Survivors

Exercise Most Important Lifestyle Change for Breast CA ...

Those who exercised were about 40 percent less likely to die from disease, review suggests

CMS Rule Set to Stabilize Small Health Insurance Markets

CMS Rule Set to Stabilize Small Health Insurance ...

Rule includes special enrollment period pre-enrollment verification, flexibility in level of cover

is free, fast, and customized just for you!

Already a member?

Sign In Now »